ELEVAI Labs Signs Exclusive Worldwide Manufacturing Agreement And License Agreement With INmune Bio Granting ELEVAI A License To Use INmune's EMx Technology
Portfolio Pulse from Benzinga Newsdesk
ELEVAI Labs has entered into an exclusive worldwide manufacturing and license agreement with INmune Bio. Under this agreement, ELEVAI is granted a license to use INmune's proprietary EMx technology. This partnership aims to leverage INmune's technology to enhance ELEVAI's product offerings.
January 16, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ELEVAI Labs has secured an exclusive license to use INmune Bio's EMx technology, which could potentially enhance its product development and market reach.
The exclusive license agreement with INmune Bio allows ELEVAI to utilize the EMx technology, which could lead to the development of new products and give the company a competitive edge. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in ELAB's stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
INmune Bio has licensed its EMx technology to ELEVAI Labs, which may result in revenue from licensing fees and strengthen its market position.
INmune Bio's agreement with ELEVAI Labs to license out its EMx technology could generate licensing revenue and validate the company's technology, which may be seen as a positive development by investors. This could lead to a short-term positive impact on INMB's stock price.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70